Identifying and Managing Barostim Patients: How APPs are Leading the Way In this on demand webinar, Dr. Philip Adamson, Chief Medical Officer at CVRx, alongside Melissa Wendell, FNP-BC,... Read More
How Duke is Improving Outcomes and Navigating Reimbursement For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works... Read More
Barostim Late-Breaking Data from THT 2025: Roundtable Discussion with Dr. Phil Adamson Following THT 2025, Dr. Phil Adamson, Chief Medical Officer of CVRx, led a virtual roundtable discussion with Dr.... Read More
